Impax Laboratories Stock Price, News & Analysis (NASDAQ:IPXL)

$16.85 0.40 (2.43 %)
(As of 11/21/2017 04:00 PM ET)
Previous Close$16.45
Today's Range$16.55 - $16.95
52-Week Range$7.75 - $25.70
Volume607,727 shs
Average Volume1.85 million shs
Market Capitalization$1.24 billion
P/E Ratio24.41
Dividend YieldN/A
Beta0.99

About Impax Laboratories (NASDAQ:IPXL)

Impax Laboratories logoImpax Laboratories, Inc. is a specialty pharmaceutical company. The Company is engaged in the development, manufacture and marketing of bioequivalent pharmaceutical products (generics), in addition to the development and marketing of branded products. Its segments include Impax Generics and Impax Specialty Pharma. The Impax Generics segment is focused on the development, manufacture, sale and distribution of its generic products, which are the pharmaceutical and therapeutic equivalents of brand-name drug products and are marketed under their established drug names. The Impax Specialty Pharma segment is engaged in the promotion, sale and distribution of several branded products, including its branded pharmaceutical product, Rytary, an extended release oral capsule formulation of carbidopa-levodopa for the treatment of Parkinson's disease, post-encephalitic Parkinsonism and Parkinsonism, and Zomig (zolmitriptan) products, indicated for the treatment of migraine headaches.


Industry, Sector and Symbol:
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Sector: Healthcare
  • Symbol: NASDAQ:IPXL
  • CUSIP: 45256B10
  • Web: www.impaxlabs.com
Debt:
  • Debt-to-Equity Ratio: 1.59%
  • Current Ratio: 1.81%
  • Quick Ratio: 1.32%
Price-To-Earnings:
  • Trailing P/E Ratio: 24.41
  • Forward P/E Ratio: 26.75
  • P/E Growth: 1.05
Sales & Book Value:
  • Annual Sales: $824.43 million
  • Price / Sales: 1.51
  • Cash Flow: $2.36 per share
  • Price / Cash: 7.13
  • Book Value: $8.45 per share
  • Price / Book: 1.99
Profitability:
  • Trailing EPS: ($6.25)
  • Net Income: $-472,030,000.00
  • Net Margins: -56.59%
  • Return on Equity: 9.06%
  • Return on Assets: 2.87%
Misc:
  • Employees: 1,495
  • Outstanding Shares: 74,110,000
 

Frequently Asked Questions for Impax Laboratories (NASDAQ:IPXL)

What is Impax Laboratories' stock symbol?

Impax Laboratories trades on the NASDAQ under the ticker symbol "IPXL."

How were Impax Laboratories' earnings last quarter?

Impax Laboratories, Inc. (NASDAQ:IPXL) announced its quarterly earnings results on Thursday, November, 9th. The specialty pharmaceutical company reported $0.23 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $0.20 by $0.03. The specialty pharmaceutical company had revenue of $206.40 million for the quarter, compared to analyst estimates of $208.38 million. Impax Laboratories had a positive return on equity of 9.06% and a negative net margin of 56.59%. Impax Laboratories's quarterly revenue was down 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.37 EPS. View Impax Laboratories' Earnings History.

What guidance has Impax Laboratories issued on next quarter's earnings?

Impax Laboratories issued an update on its FY17 earnings guidance on Thursday, November, 9th. The company provided EPS guidance of $0.60-0.65 for the period, compared to the Thomson Reuters consensus estimate of $0.70.

Where is Impax Laboratories' stock going? Where will Impax Laboratories' stock price be in 2017?

13 brokerages have issued 1-year target prices for Impax Laboratories' stock. Their predictions range from $10.00 to $35.00. On average, they expect Impax Laboratories' stock price to reach $20.31 in the next year. View Analyst Ratings for Impax Laboratories.

What are Wall Street analysts saying about Impax Laboratories stock?

Here are some recent quotes from research analysts about Impax Laboratories stock:

  • 1. According to Zacks Investment Research, "Impax’s Generics segment is facing competitive and pricing pressure, which is expected to persist through 2017. However, epinephrine auto-injector sales have picked up The company is taking steps to reduce costs and improve efficiencies, which may save an estimated $130 million by the end of 2019. Moreover, the company’s manufacturing facilities have been hampered by quality control issues since 2011, which delayed Rytary’s approval. The merger with Amneal Pharma is a positive for Impax as it will have a diverse pipeline with more than 300 products under review or late stage development. However, the generics market is highly crowded and Impax faces stiff competition from other major companies. Impax’s shares have outperformed the industry so far this year. Estimates have remained stable ahead of the Q3 earnings results. The company has a mixed record of earnings surprises in recent quarters." (10/20/2017)
  • 2. Cantor Fitzgerald analysts commented, "We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with IPXL in attendance." (9/25/2017)
  • 3. Guggenheim analysts commented, "Impax (IPXL, BUY, $12.70) named Paul Bisaro as its new, full-time CEO earlier today, which increases our confidence that there could be upside to consensus expectations in '17+. Bisaro has 25 years of generic and branded pharma experience, with an impressive track record of execution and transformation at companies like Allergan (AGN, NEUTRAL, $237.33) and its predecessors and Barr Pharmaceuticals (acquired by TEVA [BUY, $32.76] in 2010). Bisaro is also on the Board of Directors of AGN and Zoetis (ZTS, BUY, $53.85)." (3/27/2017)
  • 4. Royal Bank Of Canada analysts commented, "The stock was down -35% following IPXL's 4Q results and first-time 2017 update (no revenue or EPS given, as expected). We continue to see a number of generic headwinds that will linger as IPXL pursues a leadership change and what we see as needed review of strategic positioning. We lower EPS and target to reflect continued challenges. Remain Sector Perform." (3/2/2017)

Are investors shorting Impax Laboratories?

Impax Laboratories saw a increase in short interest in October. As of October 31st, there was short interest totalling 10,733,053 shares, an increase of 53.1% from the October 13th total of 7,009,897 shares. Based on an average daily volume of 3,250,995 shares, the short-interest ratio is presently 3.3 days. Approximately 15.7% of the company's stock are sold short.

Who are some of Impax Laboratories' key competitors?

Who are Impax Laboratories' key executives?

Impax Laboratories' management team includes the folowing people:

  • Robert L. Burr, Independent Chairman of the Board (Age 66)
  • Paul M. Bisaro, President, Chief Executive Officer, Director (Age 56)
  • Bryan M. Reasons, Chief Financial Officer, Senior Vice President - Finance (Age 49)
  • Douglas S Boothe, President - Generics Division (Age 53)
  • Michael J. Nestor, President - Impax Specialty Pharmaceutical Division (Age 64)
  • Mark A. Schlossberg Esq., Senior Vice President, General Counsel, Corporate Secretary (Age 56)
  • Jeffrey D. Nornhold, Senior Vice President - Technical Operations (Age 51)
  • J. Kevin Buchi, Director (Age 61)
  • Janet S Vergis, Director (Age 52)
  • Leslie Z. Benet Ph.D., Independent Director (Age 79)

Who owns Impax Laboratories stock?

Impax Laboratories' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Fosun International Ltd (5.20%), SHANGHAI FOSUN PHARMACEUTICAL (GROUP) COMPANY ., LTD. (5.19%), Dimensional Fund Advisors LP (4.03%), Frontier Capital Management Co. LLC (2.26%), Fisher Asset Management LLC (2.08%) and Janus Henderson Group PLC (1.90%). Company insiders that own Impax Laboratories stock include Leslie Z Benet and Michael Nestor. View Institutional Ownership Trends for Impax Laboratories.

Who sold Impax Laboratories stock? Who is selling Impax Laboratories stock?

Impax Laboratories' stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., Dimensional Fund Advisors LP, Canada Pension Plan Investment Board, State of Wisconsin Investment Board, Sector Gamma AS, OxFORD Asset Management LLP, Sivik Global Healthcare LLC and California State Teachers Retirement System. View Insider Buying and Selling for Impax Laboratories.

Who bought Impax Laboratories stock? Who is buying Impax Laboratories stock?

Impax Laboratories' stock was purchased by a variety of institutional investors in the last quarter, including Fosun International Ltd, Fisher Asset Management LLC, Janus Henderson Group PLC, Alyeska Investment Group L.P., Commonwealth of Pennsylvania Public School Empls Retrmt SYS, WINTON GROUP Ltd, Engineers Gate Manager LP and Hillsdale Investment Management Inc.. View Insider Buying and Selling for Impax Laboratories.

How do I buy Impax Laboratories stock?

Shares of Impax Laboratories can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Impax Laboratories' stock price today?

One share of Impax Laboratories stock can currently be purchased for approximately $16.85.

How big of a company is Impax Laboratories?

Impax Laboratories has a market capitalization of $1.24 billion and generates $824.43 million in revenue each year. The specialty pharmaceutical company earns $-472,030,000.00 in net income (profit) each year or ($6.25) on an earnings per share basis. Impax Laboratories employs 1,495 workers across the globe.

How can I contact Impax Laboratories?

Impax Laboratories' mailing address is 30831 Huntwood Ave, HAYWARD, CA 94544-7003, United States. The specialty pharmaceutical company can be reached via phone at +1-510-2406000 or via email at [email protected]


MarketBeat Community Rating for Impax Laboratories (NASDAQ IPXL)

Community Ranking:  2.0 out of 5 (star star)
Outperform Votes:  288 (Vote Outperform)
Underperform Votes:  435 (Vote Underperform)
Total Votes:  723
MarketBeat's community ratings are surveys of what our community members think about Impax Laboratories and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Impax Laboratories (NASDAQ:IPXL)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 8 Hold Ratings, 5 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 2.38)
Consensus Price Target: $20.31 (20.52% upside)

Consensus Price Target History for Impax Laboratories (NASDAQ:IPXL)

Price Target History for Impax Laboratories (NASDAQ:IPXL)

Analysts' Ratings History for Impax Laboratories (NASDAQ:IPXL)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/10/2017Cowen and CompanyReiterated RatingHold$16.00N/AView Rating Details
11/10/2017Cantor FitzgeraldBoost Price TargetOverweight$25.00 -> $35.00N/AView Rating Details
10/17/2017Royal Bank Of CanadaSet Price TargetHold$17.00N/AView Rating Details
10/17/2017Canaccord GenuitySet Price TargetHold$19.00N/AView Rating Details
9/28/2017Goldman Sachs Group, Inc. (The)Initiated CoverageNeutral$20.00HighView Rating Details
9/23/2017BTIG ResearchReiterated RatingBuy$20.00 -> $27.00LowView Rating Details
9/19/2017Deutsche Bank AGReiterated RatingBuy$23.00LowView Rating Details
9/19/2017Citigroup Inc.Boost Price TargetBuy$23.00LowView Rating Details
9/17/2017Piper Jaffray CompaniesReiterated RatingHold$17.00LowView Rating Details
6/23/2017BMO Capital MarketsReiterated RatingHold$16.00LowView Rating Details
6/12/2017Janney Montgomery ScottReiterated RatingNeutral$21.00HighView Rating Details
3/27/2017GuggenheimReiterated RatingBuy$20.00LowView Rating Details
3/8/2017Susquehanna Bancshares IncDowngradePositive -> Neutral$18.00 -> $10.00LowView Rating Details
11/14/2016WallachBeth CapitalDowngradeBuy -> Hold$30.00 -> $18.00N/AView Rating Details
11/7/2016Bank of America CorporationDowngradeNeutral -> Underperform$19.00N/AView Rating Details
8/15/2016Northland SecuritiesUpgradeMarket Perform -> Outperform$30.00N/AView Rating Details
8/10/2016Leerink SwannLower Price TargetMarket Perform$33.00 -> $24.00N/AView Rating Details
6/1/2016J P Morgan Chase & CoInitiated CoverageNeutral$47.00N/AView Rating Details
3/2/2016NomuraReiterated RatingHoldN/AView Rating Details
2/17/2016Raymond James Financial, Inc.UpgradeUnderperform -> Market PerformN/AView Rating Details
(Data available from 11/21/2015 forward)

Earnings

Earnings History and Estimates Chart for Impax Laboratories (NASDAQ:IPXL)

Earnings by Quarter for Impax Laboratories (NASDAQ:IPXL)

Earnings History by Quarter for Impax Laboratories (NASDAQ IPXL)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/9/2017Q3 2017$0.20$0.23$208.38 million$206.40 millionViewN/AView Earnings Details
8/9/2017Q2 2017$0.14$0.18$195.62 million$202.08 millionViewListenView Earnings Details
5/10/2017Q1 2017$0.12$0.11$193.17 million$184.40 millionViewN/AView Earnings Details
3/1/2017Q416$0.16$0.16$219.54 million$198.40 millionViewListenView Earnings Details
11/9/2016Q316$0.40$0.37$234.87 million$228.00 millionViewListenView Earnings Details
8/9/2016Q216$0.32$0.21$223.67 million$173.00 millionViewN/AView Earnings Details
5/10/2016Q116$0.39$0.43$241.84 million$226.00 millionViewListenView Earnings Details
2/22/2016Q415$0.44$0.62$223.23 million$282.10 millionViewListenView Earnings Details
11/9/2015Q315$0.39$0.40$214.69 million$221.10 millionViewN/AView Earnings Details
8/10/2015Q215$0.35$0.34$200.68 million$214.20 millionViewListenView Earnings Details
5/11/2015Q115$0.18$0.09$146.00 million$143.10 millionViewListenView Earnings Details
2/24/2015Q414$0.11$0.16$125.50 million$131.20 millionViewN/AView Earnings Details
11/4/2014Q314$0.31$0.33$148.36 million$145.63 millionViewN/AView Earnings Details
8/6/2014Q214$0.39$0.60$155.97 million$188.10 millionViewN/AView Earnings Details
5/1/2014Q114$0.13$0.24$97.80 million$118.70 millionViewN/AView Earnings Details
2/20/2014Q413$0.03($0.14)$119.01 million$100.74 millionViewN/AView Earnings Details
11/4/2013Q313($0.08)$0.25$111.83 million$115.75 millionViewN/AView Earnings Details
8/8/2013Q2 2013$0.04$0.08$120.75 million$129.63 millionViewN/AView Earnings Details
5/1/2013Q1 2013$0.21$0.37$129.12 million$148.50 millionViewN/AView Earnings Details
2/25/2013Q4 2012$0.19$0.30$127.03 million$141.10 millionViewN/AView Earnings Details
10/30/2012Q312$0.49$0.48$160.76 million$145.60 millionViewN/AView Earnings Details
7/31/2012$0.44$0.60ViewN/AView Earnings Details
5/1/2012$0.45$0.52ViewN/AView Earnings Details
2/28/2012$0.19$0.33ViewN/AView Earnings Details
11/1/2011$0.20$0.30ViewN/AView Earnings Details
8/2/2011$0.18$0.19ViewN/AView Earnings Details
5/3/2011$0.15$0.21ViewN/AView Earnings Details
2/24/2011$0.22$0.23ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Impax Laboratories (NASDAQ:IPXL)
2017 EPS Consensus Estimate: $0.87
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171$0.13$0.13$0.13
Q2 20171$0.17$0.17$0.17
Q3 20171$0.22$0.22$0.22
Q4 20171$0.35$0.35$0.35
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Impax Laboratories (NASDAQ:IPXL)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Impax Laboratories (NASDAQ IPXL)

Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 86.09%
Insider Trades by Quarter for Impax Laboratories (NASDAQ:IPXL)
Institutional Ownership by Quarter for Impax Laboratories (NASDAQ:IPXL)

Insider Trades by Quarter for Impax Laboratories (NASDAQ IPXL)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/31/2017Michael NestorInsiderSell1,130$15.00$16,950.00View SEC Filing  
5/17/2017Michael NestorInsiderSell857$16.48$14,123.36View SEC Filing  
5/12/2017Michael NestorInsiderSell700$17.11$11,977.00View SEC Filing  
8/15/2016Leslie Z BenetDirectorSell10,092$22.81$230,198.52View SEC Filing  
9/11/2015Mark A SchlossbergSVPSell7,457$43.30$322,888.10View SEC Filing  
9/10/2015Michael NestorInsiderSell5,000$43.56$217,800.00View SEC Filing  
8/31/2015Michael MarkbreiterDirectorSell28,000$41.70$1,167,600.00View SEC Filing  
8/27/2015Mark A SchlossbergSVPSell4,649$43.41$201,813.09View SEC Filing  
8/27/2015Peter R TerreriDirectorSell4,833$43.93$212,313.69View SEC Filing  
8/26/2015Michael MarkbreiterDirectorSell19,399$42.24$819,413.76View SEC Filing  
6/6/2014Larry HsuDirectorSell100,000$28.38$2,838,000.00View SEC Filing  
5/27/2014Peter R TerreriDirectorSell3,000$28.00$84,000.00View SEC Filing  
5/22/2014Larry HsuDirectorSell50,000$27.22$1,361,000.00View SEC Filing  
5/21/2014Larry HsuDirectorSell3,800$26.53$100,814.00View SEC Filing  
5/16/2014Nigel FlemingDirectorSell1,900$25.72$48,868.00View SEC Filing  
5/12/2014Nigel FlemingDirectorSell1,333$26.58$35,431.14View SEC Filing  
5/8/2014Michael MarkbreiterDirectorSell12,500$26.44$330,500.00View SEC Filing  
5/6/2014Larry HsuDirectorSell219,386$26.28$5,765,464.08View SEC Filing  
3/11/2014Michael MarkbreiterDirectorSell4,000$27.54$110,160.00View SEC Filing  
1/8/2014Robert BurrDirectorSell1,500$24.31$36,465.00View SEC Filing  
11/13/2013Robert BurrDirectorSell1,500$22.98$34,470.00View SEC Filing  
10/9/2013Robert BurrDirectorSell1,500$20.10$30,150.00View SEC Filing  
9/11/2013Robert BurrDirectorSell1,500$20.87$31,305.00View SEC Filing  
8/14/2013Robert BurrDirectorSell1,500$21.15$31,725.00View SEC Filing  
7/10/2013Robert L BurrDirectorSell1,500$20.26$30,390.00View SEC Filing  
6/12/2013Robert L BurrDirectorSell1,500$18.80$28,200.00View SEC Filing  
5/8/2013Robert L BurrDirectorSell1,500$16.35$24,525.00View SEC Filing  
5/1/2013Peter R TerreriDirectorSell3,450$17.39$59,995.50View SEC Filing  
3/12/2013Larry HsuCEOBuy7,000$16.88$118,160.00View SEC Filing  
3/12/2013Mark A SchlossbergSVPBuy1,000$16.73$16,730.00View SEC Filing  
2/13/2013Robert L BurrDirectorSell1,500$19.82$29,730.00View SEC Filing  
11/14/2012Robert L BurrDirectorSell1,500$19.86$29,790.00View SEC Filing  
8/20/2012Nigel FlemingDirectorSell6,000$23.99$143,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Impax Laboratories (NASDAQ IPXL)

Source:
DateHeadline
Impax Laboratories, Inc. (IPXL) Expected to Announce Quarterly Sales of $198.42 MillionImpax Laboratories, Inc. (IPXL) Expected to Announce Quarterly Sales of $198.42 Million
www.americanbankingnews.com - November 15 at 3:48 AM
FY2017 EPS Estimates for Impax Laboratories, Inc. (IPXL) Raised by Cantor FitzgeraldFY2017 EPS Estimates for Impax Laboratories, Inc. (IPXL) Raised by Cantor Fitzgerald
www.americanbankingnews.com - November 14 at 8:44 AM
 Brokerages Anticipate Impax Laboratories, Inc. (IPXL) to Post $0.22 EPS Brokerages Anticipate Impax Laboratories, Inc. (IPXL) to Post $0.22 EPS
www.americanbankingnews.com - November 13 at 9:16 PM
Impax Laboratories, Inc. (IPXL) Price Target Increased to $35.00 by Analysts at Cantor FitzgeraldImpax Laboratories, Inc. (IPXL) Price Target Increased to $35.00 by Analysts at Cantor Fitzgerald
www.americanbankingnews.com - November 12 at 8:32 AM
Impax Reports Third Quarter 2017 ResultsImpax Reports Third Quarter 2017 Results
finance.yahoo.com - November 11 at 12:49 PM
Impax Labs reports 3Q lossImpax Labs reports 3Q loss
finance.yahoo.com - November 11 at 12:49 PM
Edited Transcript of IPXL earnings conference call or presentation 9-Nov-17 1:30pm GMTEdited Transcript of IPXL earnings conference call or presentation 9-Nov-17 1:30pm GMT
finance.yahoo.com - November 11 at 12:49 PM
Impax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/YImpax (IPXL) Q3 Earnings & Revenues Beat Estimates, Fall Y/Y
finance.yahoo.com - November 11 at 12:48 PM
Impax Laboratories, Inc. (IPXL) Rating Reiterated by Cowen and CompanyImpax Laboratories, Inc. (IPXL) Rating Reiterated by Cowen and Company
www.americanbankingnews.com - November 11 at 10:22 AM
Short Interest in Impax Laboratories, Inc. (IPXL) Rises By 53.1%Short Interest in Impax Laboratories, Inc. (IPXL) Rises By 53.1%
www.americanbankingnews.com - November 11 at 3:40 AM
Impax Laboratories, Inc. (IPXL) Releases Quarterly  Earnings Results, Beats Expectations By $0.03 EPSImpax Laboratories, Inc. (IPXL) Releases Quarterly Earnings Results, Beats Expectations By $0.03 EPS
www.americanbankingnews.com - November 9 at 4:34 PM
Impax Laboratories, Inc. (IPXL) Releases FY17 Earnings GuidanceImpax Laboratories, Inc. (IPXL) Releases FY17 Earnings Guidance
www.americanbankingnews.com - November 9 at 9:28 AM
Reviewing Impax Laboratories (IPXL) and Akcea Therapeutics (AKCA)Reviewing Impax Laboratories (IPXL) and Akcea Therapeutics (AKCA)
www.americanbankingnews.com - November 8 at 2:28 PM
Impax Laboratories, Inc. (IPXL) Given Average Rating of "Hold" by AnalystsImpax Laboratories, Inc. (IPXL) Given Average Rating of "Hold" by Analysts
www.americanbankingnews.com - November 5 at 9:24 AM
Today's charts: Under Armour sinks; Mylan drops on drug-pricing probe; Mondelez 3Q profit soars 81%Today's charts: Under Armour sinks; Mylan drops on drug-pricing probe; Mondelez 3Q profit soars 81%
finance.yahoo.com - November 3 at 8:42 AM
Impax Laboratories, Inc. (IPXL) Scheduled to Post Earnings on TuesdayImpax Laboratories, Inc. (IPXL) Scheduled to Post Earnings on Tuesday
www.americanbankingnews.com - October 31 at 8:36 AM
UBS AG Boosts Impax Laboratories, Inc. (IPXL) Price Target to $16.00UBS AG Boosts Impax Laboratories, Inc. (IPXL) Price Target to $16.00
www.americanbankingnews.com - October 30 at 7:56 PM
$203.66 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter$203.66 Million in Sales Expected for Impax Laboratories, Inc. (IPXL) This Quarter
www.americanbankingnews.com - October 26 at 4:18 PM
WeissLaw LLP Investigates Impax Laboratories, Inc. AcquisitionWeissLaw LLP Investigates Impax Laboratories, Inc. Acquisition
finance.yahoo.com - October 24 at 9:53 PM
Impax Labs stock surges 4.4% on FDA approval of generic kidney disease medication RenvelaImpax Labs stock surges 4.4% on FDA approval of generic kidney disease medication Renvela
finance.yahoo.com - October 24 at 4:51 PM
Wolf Popper LLP Investigates the Proposed Acquisition of Impax Laboratories, Inc. by Amneal Pharmaceuticals LLCWolf Popper LLP Investigates the Proposed Acquisition of Impax Laboratories, Inc. by Amneal Pharmaceuticals LLC
finance.yahoo.com - October 24 at 4:51 PM
Impax Laboratories (IPXL) Announces FDA Approval, Launch of Generic Renvela Tablets, 800 mgImpax Laboratories (IPXL) Announces FDA Approval, Launch of Generic Renvela Tablets, 800 mg
www.streetinsider.com - October 23 at 7:37 PM
Impax Laboratories Inc. (IPXL) Is Rising After FDA ApprovalImpax Laboratories Inc. (IPXL) Is Rising After FDA Approval
www.rttnews.com - October 23 at 7:37 PM
Impax Laboratories, Inc. (IPXL) Rating Lowered to Sell at Zacks Investment ResearchImpax Laboratories, Inc. (IPXL) Rating Lowered to Sell at Zacks Investment Research
www.americanbankingnews.com - October 20 at 12:32 PM
Contrasting Impax Laboratories (IPXL) & Theravance Biopharma (TBPHV)Contrasting Impax Laboratories (IPXL) & Theravance Biopharma (TBPHV)
www.americanbankingnews.com - October 18 at 8:40 PM
Impax Laboratories, Inc. (IPXL) PT Set at $17.00 by Royal Bank Of CanadaImpax Laboratories, Inc. (IPXL) PT Set at $17.00 by Royal Bank Of Canada
www.americanbankingnews.com - October 18 at 7:08 PM
Impax Lab (IPXL) and Amneal Pharmaceuticals To Combine IR Presentation - SlideshowImpax Lab (IPXL) and Amneal Pharmaceuticals To Combine IR Presentation - Slideshow
seekingalpha.com - October 18 at 4:47 PM
Generic-Drug Maker Pares Losses, But Analysts Split On MergerGeneric-Drug Maker Pares Losses, But Analysts Split On Merger
finance.yahoo.com - October 18 at 4:47 PM
Amneal And Impax To CombineAmneal And Impax To Combine
www.bizjournals.com - October 18 at 2:23 AM
Impax Laboratories (IPXL) to Merge with Amneal in All-Stock TransactionImpax Laboratories (IPXL) to Merge with Amneal in All-Stock Transaction
www.streetinsider.com - October 18 at 2:23 AM
Amneal Pharma, Impax Announce Business Combination - Quick FactsAmneal Pharma, Impax Announce Business Combination - Quick Facts
www.nasdaq.com - October 18 at 2:22 AM
Drugmakers Amneal and Impax to combineDrugmakers Amneal and Impax to combine
www.reuters.com - October 18 at 2:22 AM
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Impax Laboratories, Inc. to Amneal Pharmaceuticals LLC is Fair to ...SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Concerning Whether the Sale of Impax Laboratories, Inc. to Amneal Pharmaceuticals LLC is Fair to ...
www.businesswire.com - October 18 at 2:22 AM
UnitedHealth and Morgan Stanley climb while Impax skidsUnitedHealth and Morgan Stanley climb while Impax skids
marketbeat.com - October 17 at 6:15 PM
Canaccord Genuity Analysts Give Impax Laboratories, Inc. (IPXL) a $19.00 Price TargetCanaccord Genuity Analysts Give Impax Laboratories, Inc. (IPXL) a $19.00 Price Target
www.americanbankingnews.com - October 17 at 1:34 PM
Why Impax Laboratories Inc Is Tanking TodayWhy Impax Laboratories Inc Is Tanking Today
www.fool.com - October 17 at 1:01 PM
Short Interest Drops 16% For IPXLShort Interest Drops 16% For IPXL
www.thestreet.com - October 11 at 4:43 PM
Impax Laboratories, Inc. (IPXL) Receives Consensus Recommendation of "Hold" from BrokeragesImpax Laboratories, Inc. (IPXL) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 12:44 PM
Zacks: Brokerages Anticipate Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $203.66 MillionZacks: Brokerages Anticipate Impax Laboratories, Inc. (IPXL) Will Post Quarterly Sales of $203.66 Million
www.americanbankingnews.com - October 7 at 11:28 AM
Comparing Impax Laboratories (IPXL) & Its PeersComparing Impax Laboratories (IPXL) & Its Peers
www.americanbankingnews.com - October 7 at 12:18 AM
Impax to Report Third Quarter 2017 Results on November 9, 2017Impax to Report Third Quarter 2017 Results on November 9, 2017
finance.yahoo.com - October 4 at 5:59 PM
Financial Analysis: SCYNEXIS (SCYX) and Impax Laboratories (IPXL)Financial Analysis: SCYNEXIS (SCYX) and Impax Laboratories (IPXL)
www.americanbankingnews.com - October 1 at 10:22 AM
Impax Laboratories, Inc. (IPXL) Coverage Initiated at Goldman Sachs Group, Inc. (The)Impax Laboratories, Inc. (IPXL) Coverage Initiated at Goldman Sachs Group, Inc. (The)
www.americanbankingnews.com - September 28 at 6:20 PM
Impax Laboratories (IPXL) "Buy" Rating Reaffirmed at Cantor FitzgeraldImpax Laboratories' (IPXL) "Buy" Rating Reaffirmed at Cantor Fitzgerald
www.americanbankingnews.com - September 25 at 4:06 PM
Impax Laboratories, Inc. (IPXL) Price Target Increased to $23.00 by Analysts at Citigroup Inc.Impax Laboratories, Inc. (IPXL) Price Target Increased to $23.00 by Analysts at Citigroup Inc.
www.americanbankingnews.com - September 24 at 1:00 PM
Impax Laboratories, Inc. (IPXL) Stock Rating Reaffirmed by BTIG ResearchImpax Laboratories, Inc. (IPXL) Stock Rating Reaffirmed by BTIG Research
www.americanbankingnews.com - September 23 at 5:58 PM
Head to Head Contrast: Impax Laboratories (IPXL) vs. Its CompetitorsHead to Head Contrast: Impax Laboratories (IPXL) vs. Its Competitors
www.americanbankingnews.com - September 23 at 4:20 PM
Impax Laboratories (IPXL) vs. Aquinox Pharmaceuticals (AQXP) Head-To-Head ReviewImpax Laboratories (IPXL) vs. Aquinox Pharmaceuticals (AQXP) Head-To-Head Review
www.americanbankingnews.com - September 23 at 8:32 AM
Generic drugmaker Impax Labs in talks to merge with Amneal: WSJGeneric drugmaker Impax Labs in talks to merge with Amneal: WSJ
www.reuters.com - September 22 at 1:46 PM
Impax Laboratories Inc. (IPXL) Surged On Reports Of Merger TalksImpax Laboratories Inc. (IPXL) Surged On Reports Of Merger Talks
www.rttnews.com - September 22 at 1:46 PM

Social Media

Financials

Chart

Impax Laboratories (NASDAQ IPXL) Chart for Tuesday, November, 21, 2017
Loading chart…

This page was last updated on 11/21/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.